Viatris Inc. filed a Form 8-K on November 17, 2026, disclosing the completion of its acquisition of Pacira BioSciences, Inc. through a tender offer and subsequent merger finalized on that same date.
Key Highlights
- Tender offer price: $36.50 per share in cash, net of applicable withholding taxes and without interest, for all outstanding Pacira common stock.
- Shares tendered: 32,929,780 shares were validly tendered and not validly withdrawn, representing approximately 66.46% of Pacira shares outstanding immediately prior to the expiration.
- Offer expiration: The offer and related withdrawal rights expired at one minute after 11:59 p.m., Eastern Time, on November 16, 2026.
- Total consideration: The aggregate amount to be paid in the offer and the merger is approximately $1.69 billion, excluding related fees and expenses.
- Merger structure: The merger was effected without a stockholder vote pursuant to Section 251(h) of the Delaware General Corporation Law, with Pacira continuing as a wholly owned subsidiary of Viatris.
- Funding: Viatris and the purchaser will fund the acquisition through a combination of cash on hand and short-term borrowings, according to the filing.
Viatris Closes Pacira Merger After Tender Offer Minimum Condition Met
According to the Form 8-K filed with the SEC on November 17, 2026, by Viatris Inc. (NASDAQ:VTRS), the company completed its acquisition of Pacira BioSciences, Inc. on that date. The filing states that Viatris entered into an Agreement and Plan of Merger with Pacira and its wholly owned subsidiary, Peach Purchaser Sub Inc., on October 8, 2026, and that Peach Purchaser Sub Inc. commenced a tender offer on October 30, 2026 to purchase all outstanding Pacira common shares at $36.50 per share in cash.
The filing disclosed that, immediately prior to the expiration of the offer at one minute after 11:59 p.m., Eastern Time, on November 16, 2026, a total of 32,929,780 shares had been validly tendered and not validly withdrawn, representing approximately 66.46% of Pacira shares outstanding at that time. The filing states that this satisfied the Minimum Condition as defined in the Merger Agreement, and that all other conditions to the consummation of the offer were satisfied or waived. On November 17, 2026, Peach Purchaser Sub Inc. irrevocably accepted for payment all validly tendered shares, with payment to be made promptly in accordance with the terms of the offer and the Merger Agreement.
Following the completion of the offer, the filing states that the remaining conditions to the merger were satisfied or waived, and Peach Purchaser Sub Inc. merged with and into Pacira on November 17, 2026, without a stockholder vote in accordance with Section 251(h) of the Delaware General Corporation Law. Pacira continues as the surviving corporation and a wholly owned subsidiary of Viatris. Each Pacira share outstanding immediately prior to the effective time, subject to specified exceptions including shares held by Viatris or Pacira subsidiaries and shares subject to properly exercised appraisal rights, was converted into the right to receive the $36.50 offer price. The filing reports the aggregate consideration to be paid is approximately $1.69 billion, excluding related fees and expenses, funded through cash on hand and short-term borrowings.
What Was Disclosed
Viatris Inc. disclosed the completion of its tender offer for and merger with Pacira BioSciences, Inc., effective November 17, 2026, at a price of $36.50 per share in cash, with total consideration of approximately $1.69 billion excluding fees and expenses.




Please wait processing your request...